These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21570476)

  • 21. A safety monitoring procedure for a clinical drug development program, with application to the assessment of a novel COX-2 inhibitor.
    Bolland K; Whitehead J; Oldham M
    J Biopharm Stat; 2008; 18(4):737-49. PubMed ID: 18607805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How a US regulator can encourage new science.
    Throckmorton DC
    Clin Pharmacol Ther; 2009 Nov; 86(5):471-2. PubMed ID: 19844222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Innovative approaches in drug development.
    Chang M; Kenley S; Bull J; Chiu YY; Wang W; Wakeford C; McCarthy K
    J Biopharm Stat; 2007; 17(5):775-89. PubMed ID: 17885865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Biomarkers Consortium: on the critical path of drug discovery.
    Altar CA
    Clin Pharmacol Ther; 2008 Feb; 83(2):361-4. PubMed ID: 18183037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A guidance for renal biomarker lead optimization and use in translational pharmacodynamics.
    Ozer JS
    Drug Discov Today; 2010 Feb; 15(3-4):142-7. PubMed ID: 20026239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human microdosing; a boon or a bane?
    Seth SD; Kumar NK; Dua P
    Indian J Med Res; 2009 Aug; 130(2):202-4. PubMed ID: 19797820
    [No Abstract]   [Full Text] [Related]  

  • 28. Metabolomics for early detection of drug-induced kidney injury: review of the current status.
    Boudonck KJ; Rose DJ; Karoly ED; Lee DP; Lawton KA; Lapinskas PJ
    Bioanalysis; 2009 Dec; 1(9):1645-63. PubMed ID: 21083109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development.
    Peck RW
    Drug Discov Today; 2007 Apr; 12(7-8):289-94. PubMed ID: 17395088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
    Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
    Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valuation of biomarkers.
    Hurko O; Jones GK
    Nat Rev Drug Discov; 2011 Apr; 10(4):253-4. PubMed ID: 21455229
    [No Abstract]   [Full Text] [Related]  

  • 32. The quest for biomarkers in tuberculosis.
    Parida SK; Kaufmann SH
    Drug Discov Today; 2010 Feb; 15(3-4):148-57. PubMed ID: 19854295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements.
    Schwarz AJ; Becerra L; Upadhyay J; Anderson J; Baumgartner R; Coimbra A; Evelhoch J; Hargreaves R; Robertson B; Iyengar S; Tauscher J; Bleakman D; Borsook D
    Drug Discov Today; 2011 Jul; 16(13-14):583-93. PubMed ID: 21635967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innovative strategies for early clinical R&D.
    Butz RF; Morelli G
    IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Assessing adverse reactions in clinical trials].
    Harnisch S; Schade-Brittinger C; Rief W
    Dtsch Med Wochenschr; 2012 Jul; 137(27):1421-5. PubMed ID: 22736184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional mapping of drug response with pharmacodynamic-pharmacokinetic principles.
    Ahn K; Luo J; Berg A; Keefe D; Wu R
    Trends Pharmacol Sci; 2010 Jul; 31(7):306-11. PubMed ID: 20488563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Biomarkers Forum: harnessing the potential of biomarkers from translational research throughout clinical trials.
    Shaw M
    Expert Rev Mol Diagn; 2007 Nov; 7(6):759-60. PubMed ID: 18020905
    [No Abstract]   [Full Text] [Related]  

  • 39. Benefit-risk assessment: to quantify or not to quantify, that is the question.
    Yuan Z; Levitan B; Berlin JA
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):653-6. PubMed ID: 21538675
    [No Abstract]   [Full Text] [Related]  

  • 40. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
    Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
    Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.